908 Devices Inc.MASS決算レポート
Nasdaq · ヘルスケア · 計測及び制御装置（その他）
908 Devices Inc.は高性能な携帯型質量分析装置と分析ソリューションの開発・製造を手がける企業です。製品はライフサイエンス研究、バイオ医薬品製造、公共安全、法医学鑑定、産業プロセス監視などの分野で活用され、世界中の研究機関、製薬企業、政府機関を顧客層としています。
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| ARCH | 17.70% | 5.7M | — | 2024-02-09 |
| ARCH Venture Fund VII, L.P. | 16.40% | 5.7M | — | 2024-11-14 |
| ARK | 13.42% | 4.3M | — | 2024-01-29 |
| Ameriprise Financial, | 5.84% | 1.9M | — | 2024-02-14 |
| BlackRock, Inc. | 5.40% | 1.9M | 変動なし | 2024-11-08 |
| The Vanguard Group | 5.39% | 1.7M | — | 2024-02-13 |
| Eventide Asset Management, LLC | 4.42% | 1.4M | — | 2024-02-14 |
| Alger Associates, Inc. | 3.80% | 1.2M | — | 2023-11-13 |
| S.S. OR | 2.49% | 861.4K | ▼ -3.81pp | 2024-11-14 |
インサイダー取引
Net 90d: −$828.4K · buys $0 / sells $828.4K期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-10 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 2.7K | $1.05 | $2.8K |
| 2026-04-10 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 2.7K | $7.01 | $18.9K |
| 2026-04-10 | Brown Christopher D. | Director | Sell (open market) | 17.6K | $7.07 | $124.3K |
| 2026-04-09 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 5.4K | $1.05 | $5.7K |
| 2026-04-09 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 5.4K | $7.03 | $38.1K |
| 2026-04-09 | Brown Christopher D. | Director | Sell (open market) | 7.4K | $7.04 | $52.0K |
| 2026-04-08 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 18.6K | $1.05 | $19.5K |
| 2026-04-08 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 18.6K | $7.05 | $131.0K |
| 2026-04-08 | Brown Christopher D. | Director | Sell (open market) | 15.0K | $7.05 | $106.0K |
| 2026-03-02 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 7 | $1.05 | $7 |
1–10 of 25
1 / 3 ページ